Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced recovery of high-quality DNA from limited FFPE tissue for advancing cancer genomics.

Scientific reports·2026
Same author

Glycoprotein mucin 13 expression as a theranostic target in colorectal cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Biodegradable PCL-PLGA Electrospun Nanofibers for Localized Cancer Therapy.

ACS applied bio materials·2026
Same author

MUC13-Associated Molecular Interactome in Pancreatic Cancer.

Computational and structural biotechnology journal·2026
Same author

Scope of nanobodies in hepatopancreatobiliary oncology.

Drug discovery today·2026
Same author

Computational Repurposing and Experimental Validation of YBX1 Inhibitors in Hepatocellular Carcinoma.

Biomedicines·2026

Related Experiment Video

Updated: May 28, 2026

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

Emerging Near-Infrared Targeted Imaging Pharmaceutics for Ovarian Cancer.

Angel Phillip1, Annu Karithara1, Subhash C Chauhan2

  • 1School of Medicine, University of Texas Rio Grande Valley, Edinburg, TX 78539, USA.

Pharmaceutics
|May 27, 2026
PubMed
Summary

Near-infrared (NIR) imaging with targeted probes improves ovarian cancer detection during surgery, potentially reducing residual disease. Further trials are needed to confirm its clinical benefit for recurrence-free survival.

Keywords:
fluorophoresimage-guided therapyindocyanine greenmucinnear-infrared imagingovarian cancer

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Tissue-simulating Phantoms for Assessing Potential Near-infrared Fluorescence Imaging Applications in Breast Cancer Surgery
11:05

Tissue-simulating Phantoms for Assessing Potential Near-infrared Fluorescence Imaging Applications in Breast Cancer Surgery

Published on: September 19, 2014

Related Experiment Videos

Last Updated: May 28, 2026

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Tissue-simulating Phantoms for Assessing Potential Near-infrared Fluorescence Imaging Applications in Breast Cancer Surgery
11:05

Tissue-simulating Phantoms for Assessing Potential Near-infrared Fluorescence Imaging Applications in Breast Cancer Surgery

Published on: September 19, 2014

Area of Science:

  • Oncology
  • Surgical Imaging
  • Biomarkers

Background:

  • Intraoperative ovarian cancer detection is difficult, often missing microscopic disease.
  • Residual tumor negatively impacts surgical outcomes, recurrence, and treatment resistance.
  • Near-infrared (NIR) imaging offers enhanced visualization for improved tumor margin delineation.

Purpose of the Study:

  • To review preclinical and clinical studies on NIR image-guided strategies for ovarian cancer.
  • To evaluate tumor-targeted probes for intraoperative use.
  • To assess the efficacy and safety of NIR imaging in ovarian cancer surgery.

Main Methods:

  • Focused literature review of PubMed using keywords related to NIR imaging and ovarian cancer.
  • Inclusion of studies on probes targeting folate receptor alpha, α3-integrin, mesothelin, and CA125.
  • Analysis of probe design, delivery, imaging performance, safety, and clinical relevance.

Main Results:

  • Targeted NIR probes significantly improved tumor-to-background contrast and lesion detection sensitivity.
  • NIR imaging provided enhanced intraoperative guidance compared to conventional methods.
  • Preclinical and early clinical data show favorable safety profiles and suggest reduced residual disease and improved recurrence-free survival.

Conclusions:

  • Tumor-specific NIR imaging is a promising strategy to enhance surgical outcomes in ovarian cancer.
  • Challenges include biomarker heterogeneity, limited probe availability, and cost.
  • Large-scale randomized trials are necessary to validate efficacy and guide clinical integration.